Anti-angiogenesis therapies: Their potential in cancer management

OncoTargets and Therapy

Volumn 3, Issue , 2010, Pages 69-82

  Eichholz, Andrew ^a   Merchant, Shairoz ^a   Gaya, Andrew M ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Aflibercept; Angiogenesis; Bevacizumab; Thalidomide; Tyrosine kinase inhibitors; Vascular disrupting agents

Indexed keywords

AFLIBERCEPT; ALPHA INTERFERON; ALPHA2A INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; COMBRETASTATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DEXAMETHASONE; DOXORUBICIN; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; THALIDOMIDE; TRASTUZUMAB; UNINDEXED DRUG; VASCULAR TARGETING AGENT;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADJUVANT THERAPY; ALOPECIA; AMYLASE BLOOD LEVEL; ANAPLASTIC THYROID CANCER; ANEMIA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTIANGIOGENIC THERAPY; ARTERIAL THROMBOEMBOLISM; ARTHRALGIA; ASTHENIA; ATAXIA; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLEEDING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CHEMORADIOTHERAPY; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; DYSESTHESIA; DYSPHONIA; DYSPNEA; EPISTAXIS; FATIGUE; FETUS DISTRESS; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HAND FOOT SYNDROME; HEART DISEASE; HEART MUSCLE ISCHEMIA; HEMOPTYSIS; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; HYPERURICEMIA; HYPONATREMIA; HYPOTENSION; HYPOTHYROIDISM; INTESTINE ISCHEMIA; KIDNEY CARCINOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOCYTOPENIA; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA; NAUSEA; NEOPLASM; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PAIN; PARESTHESIA; PERFORATION; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEINURIA; RECTUM CANCER; REVIEW; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; SYNCOPE; TERATOGENICITY; THROMBOCYTOPENIA; TOXICITY; TREMOR; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR REGRESSION; TUMOR VASCULARIZATION; VENOUS THROMBOEMBOLISM; VISUAL DISORDER; VOMITING; WEIGHT REDUCTION;

EID: 84863801928     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000;6(4):389-395.
2. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604-4613.
3. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407(6801):242-248.
4. Jain RK. Molecular regulation of vessel maturation. Nat Med. 2003;9(6):685-693.
5. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307(5706):58-62.
6. Knocke TH, Weitmann HD, Feldmann HJ, Selzer E, Potter R. Intratumoral pO2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol. 1999;53(2):99-104.
7. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol. 1999;53(2):113-117.
8. Kakolyris S, Fox SB, Koukourakis M, et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. Br J Cancer. 2000;82(4):844-851.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-2342.
10. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007 20;25(12):1539-544.
11. Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013-2019.
12. Hedrick E, Kozloff M, Hainsworth J, et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: Updated results from a large observational registry in the US (BRiTE). J Clin Oncol. (Meeting Abstracts). 2006;24(18 Suppl):3536.
13. Chen HX, Mooney M, Boron M, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol. 2006;24(21):3354-3360.
14. US National Institutes of Health. Fluorouracil, leucovorin, and oxaliplatin with or without bevacizumab in treating patients who have undergone surgery for stage II or stage III colon cancer. http://clinicaltrials.gov/ct2/show/NCT0096278. Accessed Aug 17, 2009.
15. Wolmark N, Yothers G, O'Connell M, et al. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stage II or III carcinoma of the colon: Results of NSABP Protocol C-08. J Clin Oncol. 2009;27:18s(Suppl; abstr LBA14).
16. US National Institutes of Health. Combination chemotherapy with or without bevacizumab in treating patients who have undergone surgery for stage II or stage III colon cancer. http://clinicaltrials.gov/ct2/show/NCT00112918. Accessed Aug 17, 2009.
17. US National Institutes of Health. Oxaliplatin, leucovorin, and fluorouracil with and without bevacizumab in treating patients who have undergone surgery for stage II colon cancer. http://clinicaltrials.gov/ct2/show/NCT00217737. Accessed Aug 17, 2009.
18. Oncology Clinical Trials Office (University of Oxford). A multicentre international study of capecitabine +/- bevacizumab as adjuvant treatment of colorectal cancer. http://www.octo-oxford.org.uk/alltrials/trials/q2.html. Accessed Aug 17, 2009.
19. National Cancer Institute. FDA Approval for Bevacizumab. http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab. Accessed Aug 17, 2009.
20. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666-2676.
21. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo- controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol. 2008;26:1008s.
22. Robert NJ, Dieras V, Glaspy J, et al. RIBBON-1: Randomized, doubleblind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol. 2009;27:42s(abstr 1005).
23. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol. 2005;23(4):792-799.
24. United States Food and Drug Administration. Oncology Drugs Advisory Committee Meeting 5 December 2007, AVASTIN (Bevacizumab). 2008; http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4332b1-03-Genentech.pdf. Accessed Nov 29, 2009.
25. US National Institutes of Health. Bevacizumab and combination chemotherapy in treating patients who have undergone surgery for breast cancer that has spread to the lymph nodes. http://clinicaltrials. gov/ct2/show/NCT00119262. Accessed Aug 17, 2009.
26. Miller KD, O'Neill A, Perez EA, Seidman AD, Sledge GW. Phase II feasibility trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node-positive breast cancer: A trial of the Eastern Cooperative Oncology Group (E2104). J Clin Oncol. (Meeting Abstracts). 2008 May 20;26(15 Suppl):520.
27. US National Institutes of Health. BEATRICE study: A study of Avastin (bevacizumab) adjuvant therapy in triple negative breast cancer. http://clinicaltrials.gov/ct2/show/NCT00528567. Accessed Aug 17, 2009.
28. US National Institutes of Health. BETH Study: Treatment of HER2 positive breast cancer with chemotherapy plus trastuzumab vs chemotherapy plus trastuzumab plus bevacizumab. http://clinicaltrials. gov/ct2/show/NCT00625898. Accessed Aug 17, 2009.
29. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-2550.
30. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27(8):1227-1234.
31. Manegold C, von Pawel J, Zatloukal P, et al. B017704 (AVAIL): A phase III randomised study of first-line bevacizumab combined with cisplatin/gemcitabine (CG) in patients with advanced or recurrent non-squamous, non-small cell lung cancer. Ann Oncol. 2008; 19(Suppl 8):viii.
32. Cloughesy TF, Prados MD, Wen PY, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol. 2008;26 May 20 Suppl; abstr 2010b.
33. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 740-45.
34. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605):2103-2111.
35. Rini BI, Halabi S, Rosenberg JE, et al. CALGB 90206: A phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma. Paper presented at: ASCO Genitourinary Cancers Symposium 2008; San Francisco, CA, USA.
36. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27(18):3020-3026.
37. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008;71(5):1372-1380.
38. US National Institutes of Health. Temozolomide and radiation therapy with or without bevacizumab in treating patients with newly diagnosed glioblastoma or gliosarcoma. http://clinicaltrials.gov/ct2/show/NCT00884741. Accessed Aug 17, 2009.
39. US National Institutes of Health. A study of Avastin (bevacizumab) in combination with temozolomide and radiotherapy in patients with newly diagnosed glioblastoma. http://clinicaltrials.gov/ct2/show/NCT00943826. Accessed Aug 17, 2009.
40. Roche Products Limited. Summary of product characteristics: Avastin 25 mg/ml concentrate for solution for infusion. http://emc.medicines.org.uk/document.aspx?documentId=15748. Accessed Aug 17, 2009.
41. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099-7109.
42. Ratain MJ, Eisen T, Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(16):2505-2512.
43. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134.
44. Bukowski RM, Eisen T, Szczylik C, et al. Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: Survival and biomarker analysis. J Clin Oncol (Meeting Abstracts). 2007 June 20;25(18S):5023.
45. National Cancer Institute. FDA Approval for Sorafenib Tosylate. http://www.cancer.gov/cancertopics/druginfo/fda-sorafenib-tosylate. Accessed Sept 16, 2009.
46. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378-390.
47. Bayer plc. Summary of product characteristics: Nexavar 200 mg f ilm-coated tablets. http://emc.medicines.org.uk/document.aspx?documentId=18520. Accessed Sept 30, 2009.
48. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327-337.
49. Motzer RJ, Rini BI, Bukowski RM, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295(21):2516-2524.
50. Motzer RJ, Michaelson MD, Redman BG, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24(1):16-24.
51. Stein MN, Flaherty KT. CCR drug updates: sorafenib and sunitinib in renal cell carcinoma. Clin Cancer Res. 2007;13(13):3765-3770.
52. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124.
53. National Cancer Institute. FDA Approval for Sunitinib Malate. http://www.cancer.gov/cancertopics/druginfo/fda-sunitinib-malate.
54. US National Institutes of Health. A clinical trial comparing efficacy and safety of sunitinib versus placebo for the treatment of patients at high risk of recurrent renal cell cancer (S-TRAC). http://clinicaltrials.gov/ct2/show/NCT00375674. Accessed Sept 30, 2009.
55. US National Institutes of Health. Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery. http://clinicaltrials.gov/ct2/show/NCT00326898. Accessed Sept 30, 2009.
56. Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19 Suppl 2:ii35-ii38.
57. Rubin BP. Gastrointestinal stromal tumours: an update. Histopathology. 2006;48(1):83-96.
58. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299(5607): 708-710.
59. Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005;23(24):5795-5804.
60. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-1338.
61. Demetri GD, Huang X, Garrett CR, et al. Novel statistical analysis of long-term survival to account for crossover in a phase III trial of sunitinib (SU) vs placebo (PL) in advanced GIST after imatinib (IM) failure. J Clin Oncol. (Meeting Abstracts). 2008;26(May 20 Suppl): abstr 10524.
62. Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol. 2009;6(10):569-579.
63. Aigner A, Butscheid M, Kunkel P, et al. An FGF-binding protein (FGF-BP) exerts its biological function by parallel paracrine stimulation of tumor cell and endothelial cell proliferation through FGF-2 release. Int J Cancer. 2001;92(4):510-517.
64. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16(2):159-178.
65. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91(9): 4082-4085.
66. Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology. 1996;31(2-3):213-221.
67. Turk BE, Jiang H, Liu JO. Binding of thalidomide to alpha1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production. Proc Natl Acad Sci U S A. 1996;93(15):7552-7556.
68. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348(19):1875-1883.
69. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med. 1996;335(2):91-97.
70. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24(3):431-436.
71. Rajkumar SV, Rosinol L, Hussein M, et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol. 2008;26(13):2171-2177.
72. Cavo M, Zamagni E, Tosi P, et al. Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood. 2005;106(1):35-39.
73. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367(9513):825-831.
74. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reducedintensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-1218.
75. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22): 3664-3670.
76. Celgene Ltd. Summary of product characteristics: Thalidomide Pharmion 50 mg Hard Capsules. http://emc.medicines.org.uk/document.aspx?documentId=21005. Accessed Aug 17, 2009.
77. Celgene Ltd. THALOMID (thalidomide): S.T.E.P.S. Program. http://www.thalomid.com/steps_program.aspx.
78. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22(2):414-423.
79. Rajkumar SV, Hayman S, Gertz MA, et al. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol. 2002;20(21):4319-4323.
80. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98(5):1614-1615.
81. Horne MK, 3rd, Figg WD, Arlen P, et al. Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy. 2003;23(3):315-318.
82. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99(17):11393-11398.
83. US National Institutes of Health. Topotecan with or without aflibercept in treating patients with extensive-stage small cell lung cancer. http://clinicaltrials.gov/ct2/show/NCT00828139. Accessed Aug 17, 2009.
84. US National Institutes of Health. Aflibercept versus placebo in combination with irinotecan and 5-FU in the treatment of patients with metastatic colorectal cancer after failure of an oxaliplatin based regimen (VELOUR). http://clinicaltrials.gov/ct2/show/NCT00561470. Accessed Aug 17, 2009.
85. US National Institutes of Health. A study of alibercept versus placebo in patients with second-line docetaxel for locally advanced or metastatic non-small-cell lung cancer (VITAL). http://clinicaltrials.gov/ct2/show/NCT00532155. Accessed Aug 17, 2009.
86. US National Institutes of Health. Aflibercept in combination with docetaxel in metastatic androgen independent prostate cancer (VENICE). http://clinicaltrials.gov/ct2/show/NCT00519285. Accessed Aug 17, 2009.
87. Chu QS. Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors. Expert Opin Biol Ther. 2009;9(2):263-271.
88. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res. 2001;61(17):6413-6422.
89. Thorpe PE, Chaplin DJ, Blakey DC. The first international conference on vascular targeting: meeting overview. Cancer Res. 2003;63(5): 1144-1147.
90. Gaya AM, Rustin GJ. Vascular disrupting agents: a new class of drug in cancer therapy. Clin Oncol (R Coll Radiol). 2005;17(4): 277-290.
91. Lippert JW 3rd. Vascular disrupting agents. Bioorg Med Chem. 2007;15(2):605-615.
92. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res. 1999;59(7):1626-1634.
93. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin- A4 phosphate (CA4P). Expert Opin Investig Drugs. 2009;18(2): 189-197.
94. Rustin G, Nathan P, Boxhall J, et al. A Phase Ib trial of combretastatin A-4 phosphate (CA4P) in combination with carboplatin or paclitaxel chemotherapy in patients with advanced cancer. [abstract]. J Clin Oncol. 2005;23:3013.
95. Ng Q, Goh V, Carnell D, et al. Phase Ib trial of Combretastatin A4 Phosphate (CA4P) in combination with radiotherapy (RT): Initial clinical results. [abstract 3117]. American Society of Clinical Oncology Annual Meeting. Orlando, FL, USA 2005.
96. Akerley W, Schabel M, Morrell G, et al. A randomized phase 2 trial of combretatstatin A4 phosphate (CA4P) in combination with paclitaxel and carboplatin to evaluate safety and efficacy in subjects with advanced imageable malignancies [abstract 14060]. American Society of Clinical Oncology Annual Meeting. Chicago, IL, USA 2007.
97. Rustin G, Jayson G, Reed N, et al. Fosbretabulin (combretastatin A-4 phosphate [CA4P]) carboplatin and paclitaxel is active in patients with platinum resistant ovarian cancer [abstract 315]. International Gynecologic Cancer Society Meeting; 2008.
98. Siemann DW, Shi W. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Anticancer Res. 2008;28(4B):2027-2031.
99. US National Institutes of Health. Safety study of increasing doses of combretastatin in combination with bevacizumab (Avastin) in patients with advanced solid tumors. http://clinicaltrials.gov/ct2/show/NCT00395434. Accessed Aug 17, 2009.
100. US National Institutes of Health. A study to assess the effectiveness of the combination of carboplatin, paclitaxel, bevacizumab and combretastatin (CA4P) in patients with chemotherapy naïve lung cancer. http://clinicaltrials.gov/ct2/show/NCT00653939. Accessed Aug 17, 2009.
101. Landuyt W, Ahmed B, Nuyts S, et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys. 2001;49(2):443-450.
102. Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys. 2001;51(4):1018-1024.
103. Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol. 2001;60(2):155-161.
104. Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys. 1998;42(4):899-903.
105. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 1999;19(1A):189-195.
106. Ng QS, Goh V, Carnell D, et al. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2007;67(5):1375-1380.
107. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol. 2003;21(23):4428-4438.
108. Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62(12):3408-3416.
109. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol. 2003;21(15):2815-2822